Waters Corporation $WAT Shares Purchased by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG grew its holdings in shares of Waters Corporation (NYSE:WAT) by 61.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,438 shares of the medical instruments supplier’s stock after buying an additional 1,697 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Waters were worth $1,331,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Mondrian Investment Partners LTD purchased a new stake in Waters during the 3rd quarter worth $1,397,000. Vanguard Group Inc. raised its position in Waters by 3.3% in the third quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock valued at $2,295,612,000 after purchasing an additional 246,128 shares during the period. Alberta Investment Management Corp acquired a new position in shares of Waters during the third quarter worth about $4,677,000. Veritas Asset Management LLP acquired a new position in shares of Waters during the third quarter worth about $175,320,000. Finally, Deroy & Devereaux Private Investment Counsel Inc. boosted its position in shares of Waters by 41.9% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 13,802 shares of the medical instruments supplier’s stock worth $4,138,000 after buying an additional 4,077 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. HSBC began coverage on Waters in a research note on Tuesday, January 27th. They issued a “buy” rating and a $460.00 target price for the company. Barclays began coverage on Waters in a report on Tuesday, February 10th. They issued an “overweight” rating and a $400.00 price target for the company. Robert W. Baird set a $363.00 price objective on shares of Waters in a research report on Tuesday, February 10th. Guggenheim reiterated a “buy” rating and set a $440.00 price objective on shares of Waters in a research note on Tuesday, February 10th. Finally, Wolfe Research raised shares of Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 target price on the stock in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Waters has a consensus rating of “Moderate Buy” and a consensus price target of $393.84.

Waters Price Performance

Shares of NYSE WAT opened at $299.79 on Wednesday. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15. The business has a 50 day moving average price of $358.17 and a two-hundred day moving average price of $351.75. The firm has a market cap of $29.41 billion, a PE ratio of 27.84, a price-to-earnings-growth ratio of 2.11 and a beta of 1.20.

Waters (NYSE:WAT) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. The company had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. Waters had a return on equity of 34.79% and a net margin of 20.30%.Waters’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company posted $4.10 EPS. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Sell-side analysts expect that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.